New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 11, 2014
07:34 EDTRNAProsensa upgraded to Outperform from Neutral at Wedbush
Wedbush upgraded Prosena following new encouraging subset data analysis of lead drug drisapersen and full ownership potential following termination of its partnership with GlaxoSmithKline. Price target raised to $12 from $7.
News For RNA From The Last 14 Days
Check below for free stories on RNA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2014
13:54 EDTRNASarepta surges after FDA says will explore quick approval of DMD drugs
Subscribe for More Information
09:04 EDTRNAFDA says 'willing to explore' accelerated approval for DMD drugs
In response to a White House petition urging the FDA to accelerate approval for safe, effective therapies for children with Duchenne, Janet Woodcock, Director, FDA Center for Drug Evaluation and Research, said in a response, "We are willing to explore the use of all potential pathways for the approval of drugs for Duchenne muscular dystrophy, including accelerated approval, as appropriate." She added, "We share your sense of urgency to make safe and effective drugs available for patients with Duchenne muscular dystrophy as soon as possible. That's why we're actively engaged with a number of drug companies focused on developing new drugs for Duchenne muscular dystrophy, including Sarepta Therapeutics, the company developing eteplirsen, an investigational new drug for Duchenne muscular dystrophy." Shares of Sarepta (SRPT) are trading up 5%, or 97c, to $21.30 in pre-market trading. Yesterday afternoon, Wall Street Journal reported that Sarepta is limiting the role its CEO Chris Garabedian is playing in talks with the FDA. Prosensa (RNA) is also developing a treatment for Duchenne muscular dystroph, or DMD. Reference Link
July 28, 2014
06:35 EDTRNAProsensa upgraded to Buy from Neutral at Roth Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use